Omeros (OMER) Stock Looks Cheap After Its Huge Three Year Run
Omeros (OMER) has seen a significant 571.6% share price increase over the past three years, prompting an analysis of whether its current valuation is justified by earnings. Despite this surge, the stock trades at 11.5x earnings, below the Pharmaceuticals industry average, suggesting it may still be undervalued according to Simply Wall St's Fair Ratio framework. The article highlights that recent momentum from its Yartemlea launch and analyst upgrades have not fully erased the implied discount, indicating potential for a lower earnings base than the model suggests.
The Option Play Of The Week (NASDAQ:OMER)
Omeros Corporation (OMER) is poised for market dominance in the TM-TMA sector with its FDA-approved treatment, Yartemlea, leveraging initial strong sales and a monopoly. The company's financial standing is improving due to a licensing deal with Novo Nordisk, significant debt reduction, and a projected permanent positive cash flow by mid-2027. This article likely explores an option trading strategy for OMER.
Total operating expenses of Omeros Corporation – HAN:3O8
This article focuses on the total operating expenses of Omeros Corporation, traded on the Hannover Stock Exchange under the symbol HAN:3O8. It indicates that the market for this stock is currently closed with no trades recorded. The page provides an overview of financial data and resources related to Omeros Corporation.
ETFs Investing in Omeros Corporation Stocks
This article lists various Exchange Traded Funds (ETFs) that hold Omeros Corporation (3O8) stocks, sorted by market value. It provides key details for each ETF, such as issuer, management style, focus, expense ratio, assets under management (AUM), price, and performance metrics. The information aims to help investors understand the different ETF options available for investing in Omeros Corporation, highlighting the potential for diversification and reduced risk.
Omeros Corporation stock falls 3.28 percent while analysts target USD 22.00
Omeros Corporation stock dropped 3.28% to USD 19.42 despite exceeding Q2 revenue expectations with USD 28.53 million, driven by the strong commercial performance of YARTEMLEA. Cantor Fitzgerald upgraded Omeros to Overweight with a USD 22.00 price target, yet insider sales of 95,906 shares added a counterpoint to the positive news. The company's market capitalization stands at USD 1.4 billion, with the stock trading above its 52-week low.
Trading the Move, Not the Narrative: (OMER) Edition
This article provides an analysis of Omeros Corporation (NASDAQ: OMER), highlighting strong sentiment across all horizons supporting an overweight bias. It outlines three distinct AI-generated trading strategies (Position, Momentum Breakout, Risk Hedging) with specific entry, target, and stop-loss levels, and details multi-timeframe signal analysis for near-term, mid-term, and long-term horizons.
Omeros Shares Rise After Cantor Fitzgerald Upgrade
Omeros (OMER) shares experienced a significant rise, over 12% in Tuesday trading, following an upgrade by Cantor Fitzgerald. The article notes that access to the full details of this upgrade requires a premium subscription.
Press Releases about Omeros Corporation - Common Stock (Nasdaq:OMER)
This article compiles recent press releases from Omeros Corporation (OMER), detailing financial results, significant drug approvals like YARTEMLEA® for TA-TMA, and other corporate announcements. It also includes several investor alerts from law firms investigating claims on behalf of Omeros investors. The news covers periods from late 2025 through mid-2026, highlighting key developments for the biopharmaceutical company.
Omeros (OMER) finance VP exercised options and sold shares at $20.95 apiece under a trading plan.
Omeros' VP, Finance & CAO, David J. Borges, exercised options on September 22 and 23, 2026, acquiring a total of 20,000 shares at various exercise prices. Simultaneously, Borges sold 10,000 shares on each of those days at $20.95 per share under a pre-established Rule 10b5-1 trading plan. These transactions resulted in approximate gross sale proceeds of $419K and a pre-tax spread of $229K.
Form 4 Omeros Corporation For: 24 September By Investing.com
This article announces the filing of Form 4 for Omeros Corporation (OMER) on September 24. Form 4 is a document that must be filed with the U.S. Securities and Exchange Commission (SEC) whenever there is a change in the ownership of company stock by company insiders. The brief news piece provides no further details beyond the filing date.
Form 4 Omeros Corporation For: 24 September By Investing.com
This article announces the filing of a Form 4 for Omeros Corporation (OMER) on September 24. A Form 4 is a document that must be filed with the U.S. Securities and Exchange Commission (SEC) by company insiders when they trade shares of their own company's stock. It indicates changes in beneficial ownership of securities.
Omeros stock slips 1.47 percent after Cantor upgrade
Omeros stock (OMER) fell 1.47 percent after Cantor Fitzgerald upgraded its rating from Neutral to Overweight with a $22.00 price target. This upgrade followed Omeros's strong second-quarter results, which significantly exceeded revenue and EPS consensus estimates, driven by the commercial launch of its Yartemlea therapy. Despite the stock slip, Omeros remains near its 52-week high, with investors focusing on Yartemlea's potential for durable commercial growth.
Omeros Corporation stock hits 52-week high at 19.75 USD By Investing.com
Omeros Corporation (OMER) stock reached a 52-week high of $19.75, trading just 1% below this peak, driven by a 332.01% increase over the past year. The company's recent Q2 results surpassed expectations, with adjusted earnings of $0.02 per share and revenue of $28.5 million, largely due to the successful launch of its drug, Yartemlea. Following these strong results, Cantor Fitzgerald upgraded Omeros' stock rating to Overweight with a $22.00 price target.
Omeros (NASDAQ: OMER) officer to sell 10,000 shares via option exercise
An officer at Omeros Corporation (OMER), David Borges, has filed a Form 144 indicating an intent to sell 10,000 shares of common stock. These shares will be acquired through the exercise of stock options for cash on September 22, 2026, and the transaction is estimated to be valued at $184,900. The filing also notes previous Rule 10b5-1 plan sales by Borges in August 2026, ranging from 906 to 10,000 shares.
Omeros Transplant Drug Could Be Bigger than Expected, Says Analyst
Cantor Fitzgerald upgraded Omeros Corp (NASDAQ: OMER) to Overweight with a $22 price target, believing its transplant drug Yartemlea could achieve higher sales than previously anticipated. The FDA-approved drug for TA-TMA generated $28.5 million in revenue in Q2 and received NTAP status for Medicare reimbursement, leading analysts to raise peak sales forecasts to $400 million. Despite positive physician feedback and strong patient adoption, the stock's current valuation does not fully reflect Yartemlea's potential.
Omeros Corporation stock hits 52-week high at 19.75 USD By Investing.com
Omeros Corporation (NASDAQ: OMER) stock has reached a new 52-week high of $19.75, representing a 332.01% increase over the past year. This surge is attributed to investor confidence and strong Q2 results, including adjusted earnings of $0.02 per share and revenue of $28.5 million, significantly exceeding expectations due to the successful launch of its drug, Yartemlea. Cantor Fitzgerald upgraded Omeros' rating to Overweight with a $22.00 price target, though InvestingPro analysis suggests the stock might be overvalued relative to its fair value.
(OMER) Volatility Zones as Tactical Triggers
This article analyzes Omeros Corporation (NASDAQ: OMER) focusing on volatility zones as tactical triggers for trading strategies. It highlights weak near and mid-term sentiment potentially challenging a long-term positive outlook, with an exceptional 76.2:1 risk-reward short setup identified. The analysis provides AI-generated institutional trading strategies tailored for different risk profiles, including position trading, momentum breakout, and risk hedging, along with multi-timeframe signal analysis.
Price-Driven Insight from (OMER) for Rule-Based Strategy
The article provides a price-driven analysis for Omeros Corporation (NASDAQ: OMER), suggesting near-term neutral sentiment amidst mid and long-term strength. It outlines three institutional trading strategies (Position, Momentum Breakout, and Risk Hedging) with specific entry, target, and stop-loss levels. The analysis, generated by AI models, also includes a multi-timeframe signal breakdown for support and resistance levels.
Omeros VP, finance & CAO David Borges sells $206,804 in shares
David J. Borges, VP, Finance & CAO at Omeros Corp (NASDAQ:OMER), recently sold $206,804 worth of company shares through pre-established Rule 10b5-1 trading plans. Concurrently, he acquired 10,906 shares by exercising stock options. The sales occurred while Omeros stock is near its 52-week high and appears overvalued, according to InvestingPro analysis, despite the company recently surpassing Q2 earnings and revenue expectations.
Omeros Insider Sold Shares Worth $929,668, According to a Recent SEC Filing
An insider at Omeros Corporation has sold shares valued at $929,668, according to a recent SEC filing. This transaction follows other insider share sales reported in August, and comes as Omeros (OMER) is a clinical-stage biopharmaceutical company focusing on treatments for complement-mediated diseases, cancers, and addictive disorders. The company's stock was trading at $18.75 with a slight daily decrease but a year-to-date increase.
Omeros (OMER) Just Flashed Golden Cross Signal: Do You Buy?
Omeros Corporation (OMER) has displayed a "golden cross" technical signal, where its 50-day simple moving average crossed above its 200-day simple moving average, suggesting a potential bullish breakout. The stock has rallied 70.4% in the past four weeks and holds a Zacks Rank of #3 (Hold). Combined with positive earnings outlooks and recent analyst upgrades, this technical indicator makes OMER a stock to watch.
Why Omeros (OMER) Is Up 11.3% After Swinging To Profit And Stepping Up Capital Moves
Omeros Corporation (OMER) shares surged by 11.3% after the company announced a swing to net income for Q2 and H1 2026, repurchased shares, filed a shelf registration for ESOP-related stock, and expanded its board. This profitability shift and capital management, including the addition of a veteran investor to the Audit Committee, are reshaping its financial profile and governance. The company's future investment narrative now focuses on YARTEMLEA's commercial success and pipeline maturation, with analysts projecting significant revenue growth and a fair value of $33.00, suggesting a 71% upside.
Bears are Losing Control Over Omeros (OMER), Here's Why It's a 'Buy' Now
Omeros (OMER) recently formed a hammer chart pattern, signaling a potential trend reversal as buying interest emerged against a downtrend. This technical indicator, combined with a 39% increase in consensus EPS estimates for the current year and a Zacks Rank #2 (Buy), suggests that the stock is poised for an upward movement. Analysts' positive revisions and the strong Zacks Rank indicate improving prospects and a likely outperformance compared to the market.
Omeros director Thomas J. Cable disposes of 15,000 common shares for $276,772.50
Omeros director Thomas J. Cable sold 15,000 common shares for $276,772.50 on August 20, 2026, at an average price of $18.45 per share. These transactions followed his exercise of two stock option tranches for the same number of shares at $2 and $3.93. As a result, his direct holdings in Omeros common shares decreased to 35,067.
Omeros Corp (OMER) Director Thomas Cable Sells 15,000 Shares
Omeros Corp (OMER) Director Thomas Cable sold 15,000 shares of the company on August 20, 2026, for a total of $276,750, bringing his direct ownership to 35,067 shares. This sale is part of a year-long trend of insider selling with no insider purchases, which may be a cautionary signal for investors. The company's valuation metrics, including a P/E ratio of 15.05, suggest it may be trading at a discount compared to its industry peers but is more expensive relative to its own historical earnings.
Omeros (NASDAQ:OMER) Director Thomas Cable Sells 15,000 Shares
Omeros Director Thomas Cable sold 15,000 shares of OMER stock for $276,750, reducing his stake by nearly 30%. The biopharmaceutical company recently reported strong quarterly earnings, beating analyst estimates for both EPS and revenue. Omeros currently holds a "Moderate Buy" consensus rating from analysts with an average price target of $38.00.
Wall Street Analysts Believe Omeros (OMER) Could Rally 222.76%: Here's is How to Trade
Wall Street analysts project a significant upside for Omeros (OMER), with a mean price target of $43.67, suggesting a 222.8% rally from its current price of $13.53. This optimistic outlook is further supported by positive earnings estimate revisions and a Zacks Rank #1 (Strong Buy) rating for the stock. However, the article cautions investors against relying solely on price targets due to potential biases and emphasizes the importance of considering other factors like earnings estimate trends.
Omeros (NASDAQ: OMER) officer to sell 10,906 shares
An officer at Omeros (NASDAQ: OMER), David Joseph Borges, has filed a Form 144 notice indicating an intent to sell up to 10,906 shares of company common stock. These shares will be obtained through the exercise of stock options and sold for cash around August 21, 2026. The filing also notes a previous sale of 5,000 shares under a Rule 10b5-1 plan on August 13, 2026, totaling $84,750.
Omeros Corp (OMER) director lines up fresh stock sale
Omeros Corp (OMER) director Thomas Cable has filed a Form 144 notice to sell 15,000 shares of common stock, with an aggregate market value of $276,772.50. The shares will come from option exercises under a registered plan, in two tranches of 7,500 shares each on August 20, 2026. Cable also reported a sale of 7,500 shares on May 22, 2026, for $86,806.20.
Omeros (OMER) Q2 2026 Earnings Call Transcript
Omeros reported strong Q2 2026 results with Yartemlia gross sales reaching $32.2 million, a 190% increase from the previous quarter, driven by significant adoption in adult transplant centers. The company achieved positive operating cash flow of $4.1 million and strengthened its capital structure through share and note repurchases, reducing outstanding debt by 43%. Despite a negative opinion from the European Medicines Agency on Yartemlia's marketing application, Omeros is pursuing reexamination and continues to advance its MASP-2 platform and other development programs.
Omeros stock hits 52-week high at 18.16 USD
Omeros Corporation's stock reached a new 52-week high of $18.16, pushing its market capitalization to $1.31 billion, despite InvestingPro data suggesting it might be overvalued. This surge, representing a 327.45% increase over the past year, follows positive financial results for the second quarter, including adjusted earnings of $0.02 per share and $28.5 million in revenue, significantly exceeding analyst expectations, largely due to the successful launch of their drug YARTEMLEA. The stock's RSI indicates it is in overbought territory.
Omeros director Joseph L. Schocken files initial beneficial ownership statement
Omeros director Joseph L. Schocken has filed an initial SEC Form 3, disclosing beneficial ownership of 528,082 common shares. This information, dated August 12, was generated by Public Technologies (PUBT) using AI and is based on content originally published by Omeros Corporation via EDGAR on August 18, 2026.
Why Omeros (OMER) Is Up 27.5% After Swinging To Profitability And Completing Share Buyback
Omeros Corporation (OMER) saw its stock price jump 27.5% after reporting a swing to profitability in Q2 and half-year 2026, with net incomes of US$13.23 million and US$69.29 million respectively. The company also completed a share buyback of 843,187 shares and expanded its board, including the addition of Joseph Schocken, to strengthen governance. These developments, along with its pipeline advancements and a US$142.67 million ESOP-related shelf registration, are expected to influence its investment narrative, though the company's reliance on its YARTEMLEA drug remains a key focus for investors.
Omeros Corporation Reports Second Quarter 2026 Financial Results
Omeros Corporation announced its second-quarter 2026 financial results, highlighting a 190% increase in YARTEMLEA gross revenues to $32.2 million, with net income reaching $13.2 million. The company also detailed strategic financial moves, including share repurchases and convertible note buybacks, significantly strengthening its capital structure. Despite a negative opinion from the EMA for narsoplimab in Europe, Omeros continues to advance its diverse pipeline, including programs for addiction, oncology, and infectious diseases, while seeking re-examination for narsoplimab.
Omeros Appoints Veteran Investor Joseph Schocken to Board
Omeros Corporation has expanded its Board of Directors to nine members by appointing veteran investor Joseph Schocken. Schocken, founder of Broadmark Capital and instrumental in the JOBS Act, will also serve on the Audit Committee and has been granted stock options. This move aims to leverage his capital markets and policy expertise, with an analyst rating Omeros stock as a Buy with a $33.00 price target.
Omeros Corporation (NASDAQ:OMER) Receives Consensus Recommendation of "Moderate Buy" from Brokerages
Omeros Corporation (NASDAQ:OMER) has received a "Moderate Buy" consensus recommendation from brokerages, with an average 12-month price target of $38.00, significantly higher than its recent share price of $17.19. The company recently exceeded Q2 earnings expectations, reporting $0.02 EPS against an anticipated $0.27 loss, driven by a strong YARTEMLEA launch and debt reduction. Despite positive momentum, analysts have slightly trimmed longer-term EPS forecasts, and a director recently sold a portion of his shares.
Omeros: YARTEMLEA Is Off To A Blistering Start (NASDAQ:OMER)
Omeros Corporation has received a Buy rating due to YARTEMLEA's unexpectedly strong launch, generating $28.5 million in net sales and positive operating cash flow in its first full quarter. The drug's adoption is rapidly increasing across transplant centers, with high formulary approval rates and growing adult patient usage, confirming its commercial potential. Additionally, Omeros has improved its capital structure by reducing convertible debt and initiating share repurchases, lessening dilution risk and future interest expenses.
Omeros Corporation $OMER Shares Purchased by Dimensional Fund Advisors LP
Dimensional Fund Advisors LP significantly increased its stake in Omeros Corporation (NASDAQ:OMER) by 85.2% in the first quarter, now holding 179,594 shares valued at $1.9 million. This comes as Omeros recently reported strong Q2 earnings, beating analyst expectations with $0.02 EPS and $28.53 million in revenue. Despite some recent analyst downgrades, the stock maintains a "Moderate Buy" consensus rating with a $38 average price target, driven by positive sales momentum and financial initiatives.
Omeros Corp Swings To Q2 Profit On YARTEMLEA Momentum; Plans ARDS, TA-TMA Studies; Shares Rise
Omeros Corporation reported a swing to profit in Q2 2026, driven by significant revenue growth from its YARTEMLEA sales. The company also announced plans to initiate two new studies for YARTEMLEA by the end of 2026, targeting hyperinflammatory acute respiratory distress syndrome (ARDS) and prophylactic use in pediatric TA-TMA patients. Omeros shares rose following the announcement, reflecting positive investor response to its financial performance and pipeline developments.
OMEROS CORP SEC Filing (Aug 13, 2026)
This article details an SEC Form 144 filing by Omeros Corp (OMER) on August 13, 2026. The filing indicates a proposed sale of 5,000 shares of common stock, valued at $68,550.00, resulting from the exercise of stock options. The shares are to be sold through Morgan Stanley Smith Barney LLC on NASDAQ.
Top trending stocks today: ARX, OMER, TMS lead the market movers
Accelerant Holdings (ARX), Omeros Corporation (OMER), and Teamshares Inc. (TMS) were among the top trending stocks, experiencing significant surges due to major news or earnings momentum. Accelerant Holdings saw a 43.2% jump after an announced all-cash buyout, Omeros Corporation rose 24.5% following impressive Q2 results and positive cash flow, and Teamshares Inc. climbed 24.4% driven by strong analyst sentiment. Other companies like ERock, BBB Foods, Sandisk, and Aveanna Healthcare also showed strong gains, highlighting the impact of buyouts, earnings, and tech sector momentum on stock performance.
Omeros Corporation reports results for the quarter ended June 30 - Earnings Summary
Omeros Corporation has released its earnings summary for the quarter that ended on June 30. The article, sourced from Reuters, provides a concise overview of the company's financial performance during this period. Readers can access the full report for detailed insights into the results.
Omeros surges 13% on strong earnings and revenue beat
Omeros Corporation (NASDAQ:OMER) reported second-quarter results that significantly surpassed analyst expectations, driven by strong sales of its new TA-TMA treatment, YARTEMLEA. The company posted adjusted earnings per share of $0.02 and revenue of $28.5 million, significantly beating estimates. Shares of Omeros surged 13% in after-hours trading following the positive results, with management expressing satisfaction with the drug's market acceptance.
Omeros Corporation (NASDAQ: OMER) turns profitable as YARTEMLEA sales ramp
Omeros Corporation (NASDAQ: OMER) reported a significant return to profitability in Q2 2026, driven by $28.5 million in product sales from its newly launched drug YARTEMLEA. The company achieved a net income of $13.2 million for the quarter and $69.3 million for the first half of 2026, a substantial improvement from prior year losses. Despite positive earnings, Omeros recorded negative operating cash flow for the first half of 2026 and faces significant OMIDRIA royalty and convertible note obligations.
BRIEF-Omeros Corporation Q2 EPS USD 0.18
Omeros Corporation reported Q2 EPS of USD 0.18. This brief announcement was made available via Reuters and highlighted on TradingView News.
Earnings Flash (OMER) Omeros Corporation Reports Q2 Revenue $28.5M, vs. FactSet Est of $12.7M
Omeros Corporation (OMER) announced Q2 revenue of $28.5 million, significantly surpassing FactSet's estimate of $12.7 million. The company, which is a clinical-stage biopharmaceutical firm, focuses on developing therapeutics for complement-mediated diseases, cancers, and addictive disorders. They also reported earnings results for the second quarter and six months ended June 30, 2026, and their commercial product, YARTEMLEA, is approved for TA-TMA treatment.
Press Release: Omeros Corporation to Announce Second Quarter Financial Results on August 12, 2026
Omeros Corporation will announce its second quarter financial results on Wednesday, August 12, 2026. The company will also host a conference call and webcast on the same day at 4:30 p.m. Eastern Time to discuss the financial results and provide an update on recent developments.
Omeros | 8-K: Omeros Corporation Reports Second Quarter 2026 Financial Results – Conference Call Today at 4:30 p.m. ET
Omeros Corporation has released its financial results for the second quarter of 2026. The company is holding a conference call today at 4:30 p.m. ET to discuss these results. This announcement is related to an 8-K filing.
Omeros Corporation to Announce Second Quarter Financial Results on August 12, 2026
Omeros Corporation will announce its second-quarter 2026 financial results on August 12, 2026, after market close. Management will host a conference call and webcast on the same day at 4:30 p.m. Eastern Time to discuss the results and recent developments. The company is a biotechnology firm focused on developing therapeutics for various diseases, including complement-mediated conditions, cancers, and addictive disorders.
Omeros Corporation to Announce Second Quarter Financial Results on August 12, 2026
Omeros Corporation will release its second-quarter 2026 financial results on August 12, 2026, after market close. The company will host a conference call and webcast on the same day to discuss the results and recent developments. Instructions for accessing the live webcast and replay are provided.
